May 25, 2020

A drug for people with type 2 diabetes may reduce the occurrence of acute graft vs. host disease in patients who received peripheral blood stem cell transplants. 

The immune dysfunction can affect between 34% and 51% of transplant patients and is one of the major complications for patients weeks after a transplant, limiting the effectiveness of a cure for leukemia and lymphoma.

A preliminary clinical study at the Indiana University School of Medicine showed 78% of the patients in the study of the drug sitagliptin did not develop the disease, and none of them died.